Clinical implications of imipramine plasma levels for depressive illness
Autor: | Michael Shostak, James M. Perel, Shepard J. Kantor, Joseph L. Fleiss, Alexander H. Glassman |
---|---|
Rok vydání: | 1977 |
Předmět: |
Male
medicine.medical_specialty Imipramine Bipolar Disorder Desipramine Hydrochloride Individuality Placebo Gastroenterology Delusions Sex Factors Arts and Humanities (miscellaneous) Desipramine Internal medicine medicine Humans Bipolar disorder Imipramine Hydrochloride Psychiatry Depression (differential diagnoses) Dose-Response Relationship Drug Depression Plasma levels Middle Aged medicine.disease Psychiatry and Mental health Female Psychology medicine.drug |
Zdroj: | Archives of general psychiatry. 34(2) |
ISSN: | 0003-990X |
Popis: | • Sixty depressed nonschizophrenic patients were admitted to a research unit. Following one drug-free week and one week of placebo, patients received 3.5 mg/kg of imipramine hydrochloride for 28 days. Plasma levels of imipramine and its metabolite desipramine hydrochloride (desmethylimipramine) were measured three times weekly and the relationship between plasma steady-state levels and clinical outcome was examined. Steadystate levels ranged from 50 to 1,050 ng/ml. There was a statistically and clinically significant relationship between plasma levels and response. The relationship existed across the entire sample, and was accentuated when the bipolar and unipolar nondelusional populations were examined. Because a strong relationship between sex and outcome was observed, the unipolar nondelusional patients were stratified by sex and a significant relationship still persisted. Only the unipolar delusional patients failed to demonstrate an association between blood level and clinical response. ( Arch of Gen Psychiatry 34:197-204, 1977) |
Databáze: | OpenAIRE |
Externí odkaz: |